News

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...
GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...
A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.
Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...
Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...